1963. Package # 440 (Determining the risk of cancer development in a man)

This panel includes tumor markers for assessing the risk of developing the most common forms of cancer in men: prostate, lung, gastrointestinal, and liver. It is recommended for preventive screening, monitoring, and early detection of oncological pathologies.

This comprehensive analysis includes eight key tumor markers that assess the risk of developing tumors in the most vulnerable organs of the male body:

• NSE (neuron-specific enolase): a marker of neuroendocrine tumors, particularly small cell lung cancer;
• CA 19-9: a highly sensitive marker for pancreatic and gallbladder carcinoma;
• CA 72-4: a tumor marker for the stomach and mucinous tumors;
• Cyfra 21-1: a fragment of cytokeratin 19, which is elevated in lung and bladder tumors;
• PSA (total, free, and % ratio): a complex of markers for assessing prostate health, including prostate cancer screening;
• REA (CEA): a universal marker for gastrointestinal, lung, and prostate tumors;
• AFP (alpha-protein): used to diagnose liver cancer and germ cell tumors.

A combination of markers not only allows for risk identification but also the localization of a possible tumor process, monitoring disease dynamics, treatment effectiveness, and detecting relapse after remission.

Important to know:

• Tumor markers are not a diagnosis, but a tool for early risk assessment.
• They should be interpreted in conjunction with clinical data, ultrasound, MRI, biopsy, and other findings.
• Changes can be caused not only by malignant but also by benign or inflammatory processes (e.g., prostatic hyperplasia, chronic pancreatitis, cystitis).

It is indicated for men aged 40 years and older as part of an annual checkup, especially if they have:

• a strong family history (prostate, lung, stomach, liver, or pancreatic cancer);
• gastrointestinal or genitourinary symptoms;
• a history of exposure to carcinogens, smoking, chronic prostatitis, hepatitis, or cirrhosis.

Before or 7 days after instrumental prostate examinations (ultrasound, palpation, or biopsy) – to accurately assess PSA levels.

• Venous blood

In order to exclude factors that may affect the test results, we recommend to follow the preparation rules: